Atley Solutions secures long-term financing through 5M€ investment round led by Fåhraeus Startup & Growth
Gothenburg, Sweden – 2 June 2025 – Atley Solutions has secured long-term growth capital through a 5M€ investment round led by Fåhraeus Startup & Growth (FSG), a Nordic venture capital firm recognized for supporting breakthrough innovation in life sciences and technology. The round also includes continued support from existing shareholders such as Chalmers Ventures, Vätterledens Venture, Marinvest, and Chairman of the Board Erik Strömqvist.
Atley Solutions is commercializing the Atley C100, the first commercially available manufacturing system purpose-built for astatine-211 (At-211) radiopharmaceuticals. The technology addresses key manufacturing challenges, offering a robust and scalable platform that supports the transition from early research to commercial deployment.
Atley Solutions is committed to making the development of At-211-based radiopharmaceuticals more accessible. With the Atley C100, the company aims to provide researchers and clinicians with a solution to help them explore the potential of At-211-based radiopharmaceuticals and translate research into clinical possibilities.
Strategic capital allocation to support the At-211 market’s expansion into clinical trials
The newly secured capital will be allocated toward scaling Atley’s manufacturing capabilities and supporting the translation of customers’ At-211 programs into the clinic. This includes investments in technology, infrastructure, and collaborative initiatives aimed at initiating additional clinical studies over the next 12 to 24 months. These efforts will further strengthen Atley’s position as a leading provider of manufacturing solutions for targeted alpha therapies.
“We’re pleased to have secured the funding necessary to continue expanding our operations and supporting our customers in the transition toward clinical application,” said Milton Lönnroth, CEO of Atley Solutions. “The continued confidence from our existing investors, combined with the partnership of FSG, provides a strong foundation for the next phase of our growth.”
“Atley Solutions’ pioneering work in At-211 radiopharmaceutical manufacturing aligns seamlessly with our mission to support transformative life science innovations. Over the past 18 months, we’ve been following Atley’s journey closely and have been consistently impressed by their remarkable progress and dedication. We’re truly excited to help build the company and unlock new treatment possibilities in targeted alpha therapies” said Johanna Asklin, General Partner at FSG Fund and newly elected board member of Atley Solutions
